New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature

Bae JM, Lee JH, Yun JS, Han B, Young HT. Vitiligo and overt thyroid diseases: a nationwide population-based study in Korea. J Am Acad Dermatol. 2017;76(5):871–8. https://doi.org/10.1016/j.jaad.2016.12.034.

Méry-Bossard L, Bagny K, Chaby G, Khemis A, Maccari F, Marotte H, Perrot JL, Reguiai Z, Sigal ML, Avenel-Audran M, Boyé T, Grasland A, Gillard J, Jullien D, Toussirot E. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017;31(1):181–6. https://doi.org/10.1111/jdv.13759.

Mylonas A, Conrad C. Psoriasis: classical vs. paradoxical. The Ying-Yang of TNF and type I interferon. Front Immunol. 2018;9:2746. https://doi.org/10.3389/fimmu.2018.02746.

Bae JM, Kim M, Lee HH, Kim KJ, Shin H, Ju HJ, Kim GM, Park CJ, Park HJ. Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J Investig Dermatol. 2018;138(4):768–74. https://doi.org/10.1016/j.jid.2017.11.012.

Munera-Campos M, Ballesca F, Carrascoa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr. 2018;109(9):791–800. https://doi.org/10.1016/j.ad2018.04.003.

Speeckaert R, Speeckaert MM, van Geel N. Why treatments do(n’t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev. 2015;14(4):332–40. https://doi.org/10.1016/j.autrev.2014.12.003.

Speeckaert R, Mylle S, van Geel N. IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res. 2019;32(6):842–7. https://doi.org/10.1111/pcmr.12789.

Acharya P, Mathur M. Interleukin-17 level in patients with vitiligo: a systematic review and meta-analysis. Australas J Dermatol. 2020;61(2):e208–e212212. https://doi.org/10.1111/ajd.13233.

Jung JM, Lee YL, Won CH, Chang SE, Lee MW, Choi JH, Moon KC. Development of vitiligo during treatment with adalimumab: a plausible or paradoxical response? Ann Dermatol. 2015;27(5):620–1. https://doi.org/10.5021/ad.2015.27.5.620.

Toussirot E, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):e000239. https://doi.org/10.1136/rmdopen-2015-000239.